We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

42 hedge funds and large institutions have $1.65M invested in AYTU BioPharma in 2022 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,774% more capital inflows, than outflows

Capital inflows: $2.05M | Capital outflows: $71.5K

1,200% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 1

40% more funds holding

Funds holding: 30 → 42 (+12)

4.82% more ownership

Funds ownership: 9.38% → 14.2% (+4.8%)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
42
Holders Change
+12
Holders Change %
+40%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
9
Reduced
10
Closed
1
Calls
$22K
Puts
–
Net Calls
+$22K
Net Calls Change
-$127K

Top Buyers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$569K
2
SM
Sabby Management
Florida
+$479K
3
Renaissance Technologies
Renaissance Technologies
New York
+$262K
4
Walleye Capital
Walleye Capital
New York
+$221K
5
Ayrton Capital
Ayrton Capital
Connecticut
+$172K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$44.8K
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$13K
3
Two Sigma Investments
Two Sigma Investments
New York
-$5.49K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$4.01K
5
Morgan Stanley
Morgan Stanley
New York
-$1.9K

AYTU Hedge Fund Activity: Q3 2022 in Review

42 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2022, worth a combined $1.65M — down 34% from $2.5M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new AYTU positions and 1 closed out — a net gain of 12 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $569K. The largest seller was Vanguard Group, cutting an estimated $44.8K.

  • 42 institutional investors held AYTU BioPharma (AYTU) as of Q3 2022, up from 30 in Q2 2022.
  • Funds reported $1.65M of AYTU BioPharma stock for Q3 2022, down 34% quarter-over-quarter.
  • 13 funds opened new AYTU BioPharma positions in Q3 2022 and 1 closed out, a net change of +12 holders.
  • The largest AYTU BioPharma buyer in Q3 2022 was Alyeska Investment Group, an estimated $569K added.
  • The largest AYTU BioPharma seller in Q3 2022 was Vanguard Group, an estimated $44.8K sold.

Based on aggregated 13F filings for Q3 2022.